Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma

(2017) P. Hwu et al.   JOURNAL OF CLINICAL ONCOLOGY

EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma

(2010) J. W. Lee et al.   CLINICAL CANCER RESEARCH

Emerging strategies for EphA2 receptor targeting for cancer therapeutics

(2010) Manish Tandon et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer

(2009) Aparna A. Kamat et al.   CANCER

EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma

(2009) Jeong-Won Lee et al.   JNCI-Journal of the National Cancer Institute

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer

(2008) Q Chang et al.   BRITISH JOURNAL OF CANCER

A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo

(2008) D. Jackson et al.   CANCER RESEARCH

Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative Patients

(2008) Wei-Jie Yuan et al.   DIGESTIVE DISEASES AND SCIENCES

Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: Correlation with the angiogenesis and clinical outcome

(2008) Zhe Shao et al.   ORAL ONCOLOGY